About: Economic evaluation of meningococcal vaccines: considerations for the future

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Economic evaluation of meningococcal vaccines: considerations for the future Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Economic evaluation of meningococcal vaccines: considerations for the future
Creator	Towse, Adrian Christensen, Hannah Uk, Maarten, · David, · Shah, K Lorgelly, Paula Al-Janabi, Hareth Bloom, E Christensen, H Christensen@bristol, Hannah Damm, · Farkouh, Raymond Glennie, Linda Javier Diez-Domingo, · Karla Hernandez-Villafuerte, · Koonal, · Landa, Paolo Levy, · Org, Vinnys@meningitis Postma, J Salisbury, M Smith, Vinny Wright, Claire York, Laura
Source	PMC
abstract	In 2018, a panel of health economics and meningococcal disease experts convened to review methodologies, frameworks, and decision-making processes for economic evaluations of vaccines, with a focus on evaluation of vaccines targeting invasive meningococcal disease (IMD). The panel discussed vaccine evaluation methods across countries; IMD prevention benefits that are well quantified using current methods, not well quantified, or missing in current cost-effectiveness methodologies; and development of recommendations for future evaluation methods. Consensus was reached on a number of points and further consideration was deemed necessary for some topics. Experts agreed that the unpredictability of IMD complicates an accurate evaluation of meningococcal vaccine benefits and that vaccine cost-effectiveness evaluations should encompass indirect benefits, both for meningococcal vaccines and vaccines in general. In addition, the panel agreed that transparency in the vaccine decision-making process is beneficial and should be implemented when possible. Further discussion is required to ascertain: how enhancing consistency of frameworks for evaluating outcomes of vaccine introduction can be improved; reviews of existing tools used to capture quality of life; how indirect costs are considered within models; and whether and how the weighting of quality-adjusted life-years (QALY), application of QALY adjustment factors, or use of altered cost-effectiveness thresholds should be used in the economic evaluation of vaccines.
has issue date	2019-11-21(xsd:dateTime)
bibo:doi	10.1007/s10198-019-01129-z
bibo:pmid	31754924
has license	cc-by
sha1sum (hex)	9f890263add8ebfefec469c4a61ae25f3b6327dd
schema:url	https://doi.org/10.1007/s10198-019-01129-z
resource representing a document's title	Economic evaluation of meningococcal vaccines: considerations for the future
has PubMed Central identifier	PMC7072054
has PubMed identifier	31754924
schema:publication	Eur J Health Econ
resource representing a document's body	covid:9f890263add8ebfefec469c4a61ae25f3b6327dd#body_text
is schema:about of	named entity 'quality-adjusted' named entity 'general' named entity 'quantified' named entity 'factors' named entity 'Journal' named entity 'EVALUATION METHODS' named entity 'CAPTURE' named entity 'BENEFITS' named entity 'PANEL' named entity 'INDIRECT' named entity 'INTRODUCTION' named entity 'EVALUATING' named entity 'WEIGHTING' named entity 'COST-EFFECTIVENESS' named entity 'DISCUSSION' named entity 'ALTERED' covid:arg/9f890263add8ebfefec469c4a61ae25f3b6327dd named entity 'vaccine' named entity 'thresholds' named entity 'panel' named entity 'vaccines' named entity 'vaccines' named entity 'models' named entity 'indirect costs' named entity 'evaluations' named entity 'convened' named entity 'vaccination schedule' named entity 'United Kingdom' named entity 'vaccine' named entity 'cost-effectiveness' named entity 'improved' named entity 'decision-making' named entity 'IMD' named entity 'QALY' named entity 'quality of life' named entity 'health economics' named entity 'vaccines' named entity 'vaccine' named entity 'economic evaluation' named entity 'meningococcal vaccine' named entity 'evaluating' named entity 'morbidity' named entity 'vaccination' named entity 'vaccination' named entity 'cost-effectiveness' named entity 'evidence base' named entity 'limb amputation' named entity 'vaccine' named entity 'meningococcal vaccine' named entity 'meningococcal disease' named entity 'United Kingdom' named entity 'preventive health' named entity '3, 4' named entity 'national health service' named entity 'Australia' named entity 'morbidity' named entity 'Multicriteria decision analysis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software